<DOC>
	<DOCNO>NCT00817986</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability arbaclofen placarbil sustain release tablet take every 12 hour compare placebo subject acute back spasms lumbar region .</brief_summary>
	<brief_title>A Study Evaluate Safety Tolerability Arbaclofen Placarbil ( XP19986 ) Subjects With Acute Back Spasms</brief_title>
	<detailed_description />
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Arbaclofen placarbil</mesh_term>
	<mesh_term>Baclofen</mesh_term>
	<criteria>1 . Acute moderate severe muscle spasm lumbar region , indicate minimum Visual Analog Scale pain severity score 4.0 cm , begin either : within four day prior screen subject require 24hour washout Or within three day subject require 24hour washout 2 . Willing discontinue analgesic ( e.g . NSAIDS , COX2 inhibitor , acetaminophen ) , aspirin &gt; 81 mg/day , shortacting muscle relaxant ( i.e . carisoprodol , Soma® ) , herbal remedy pain least 24 hour prior first dose refrain use study ( cardioprotective dos aspirin ≤ 81 mg /day allow ) . 1 . Clinically significant abnormal neurological history examination screening ( exclude back spasm ) , include lumbar radicular symptom , spinal stenosis , foot drop , herniated nucleus pulposus , structural defect 2 . Subjects back spasm related major trauma region 3 . Subjects muscle spasm due workrelated injury subject involve injuryrelated litigation 4 . Subjects use follow medication screen : Opioids , short longacting include limited : morphine , fentanyl patch , oxycodone , tramadol ) benzodiazepine , valium lorazepam cyclobenzaprine contain drug ( e.g. , Flexeril , Amrix ) carisoprodol ( e.g. , Soma® ) within 24 hour screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Acute back pain lumbar region</keyword>
</DOC>